- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Call
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Mark Eaton
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marco Herold
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sant-Rayn Pasricha
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A new regulator of 'stemness' to create dendritic cell factories for immunotherapy
- Advanced imaging interrogation of pathogen induced NETosis
- Cancer driver deserts
- Cryo-electron microscopy of Wnt signalling complexes
- Deciphering the heterogeneity of breast cancer at the epigenetic and genetic levels
- Developing drugs to block malaria transmission
- Developing new computational tools for CRISPR genomics to advance cancer research
- Developing novel antibody-based methods for regulating apoptotic cell death
- Discovering novel paradigms to cure viral and bacterial infections
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Do membrane forces govern assembly of the deadly apoptotic pore?
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- E3 ubiquitin ligases in neurodegeneration, autoinflammation and cancer
- Engineering improved CAR-T cell therapies
- Epigenetic biomarkers of tuberculosis infection
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- Genomic rearrangement detection with third generation sequencing technology
- How does DNA damage shape disease susceptibility over a lifetime?
- How does DNA hypermutation shape the development of solid tumours?
- How platelets prevent neonatal stroke
- Human lung protective immunity to tuberculosis
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of dysregulated Tom40 in neurodegeneration
- Investigating the role of mutant p53 in cancer
- Lupus: proteasome inhibitors and inflammation
- Machine learning methods for somatic genome rearrangement detection
- Malaria: going bananas for sex
- Measurements of malaria parasite and erythrocyte membrane interactions using cutting-edge microscopy
- Measuring susceptibility of cancer cells to BH3-mimetics
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Mutational signatures of structural variation
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Revealing the epigenetic origins of immune disease
- Reversing antimalarial resistance in human malaria parasites
- Structural and functional analysis of DNA repair complexes
- Targeting human infective coronaviruses using alpaca antibodies
- Towards targeting altered glial biology in high-grade brain cancers
- Uncovering the real impact of persistent malaria infections
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding how malaria parasites sabotage acquisition of immunity
- Understanding malaria infection dynamics
- Understanding the mechanism of type I cytokine receptor activation
- Unveiling the heterogeneity of small cell lung cancer
- Using alpaca antibodies to understand malaria invasion and transmission
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to cross the blood brain barrier for drug delivery
- Using structural biology to understand programmed cell death
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Immunotherapy

Immunotherapy is an innovative treatment that modulates the body’s immune system to fight disease.
Our researchers are using their knowledge of the immune system to develop immunotherapies for cancer and immune disorders.
Immunotherapy research at the Institute
Our researchers are:
- Discovering how immune cells respond to, and kill, tumour cells with the goal of finding new ways to manipulate this process to target cancer.
- Studying whether immune cells can be harnessed to treat brain cancer without triggering significant side effects.
- Investigating whether immune checkpoint inhibitors could improve treatment of people with certain types of lung, stomach and breast cancer.
- Examining natural killer cell biology to find ways to use these cells therapeutically, for example to treat melanoma.
- Developing immunotherapies to treat coeliac disease and type 1 diabetes.
What is immunotherapy?
Your immune system plays a vital role in protecting you from harmful organisms and substances. It can fight off bacteria and viruses that invade your body, and also destroy cancer cells that arise within your body.
Unfortunately, however, cancer cells often find ways to stop your immune system from eliminating them.
Immunotherapy can help boost the body’s immune system, enabling it to successfully fight off cancer cells. This type of immunotherapy – known as cancer immunotherapy – has been hailed as one of the biggest breakthroughs in cancer treatment in a generation.
In other cases, an overactive immune system can cause disease. Some people have an immune system that inappropriately responds to harmless substances such as gluten in food. This triggers immune illnesses such as coeliac disease.
In these cases, immunotherapy aims to specifically dampen or supress these abnormal immune responses to treat the underlying cause of disease and reduce symptoms.
T cell therapy
Our researchers are working on an innovative form of immunotherapy that harnesses the body’s own immune cells to kill cancer cells.
Called CAR-T cell therapy, this treatment involves isolating a patient’s immune cells, engineering them to become ‘super killer cells’ and then reinfusing them into the patient to fight their cancer.
This technique has been successfully used to treat blood cancers but has had mixed results in solid tumours.
Our researchers are studying the biological factors contributing to the success and side effects of CAR-T cells. This work will help inform a better design and safer delivery methods.
Brain cancer is a particular focus for this work, with our researchers are aiming to find an optimum design for CAR-T cell therapy that can kill brain tumour cells with limited side effects.
Immune checkpoint inhibitors
Immune checkpoints are the brakes of the immune system, allowing immune responses to be switched off after a threat – such as a virus infection – is over. Without these brakes, uncontrolled immune responses can cause inflammatory tissue damage and autoimmune disease.
However, some cancer cells take advantage of these brakes, using them to switch off immune cells that would otherwise destroy the tumours.
Immune checkpoint inhibitors release the brakes, enabling immune cells to attack tumours.
Some of the most exciting new cancer therapies are known as anti-PD1 and anti-CTLA4 immunotherapies. Our researchers are studying these immunotherapies in several preclinical models of cancer, including lung, stomach and breast cancer.
This research could help to identify patients who may benefit from these immunotherapies and lead to future clinical trials aimed at improving patient outcomes.
Natural killer cell therapy
Natural killer cells are part of the body’s first line of defence against infections and cancer.
Our researchers are studying how natural killer cells fight cancer, with the aim of harnessing these cells to specifically detect and destroy the disease.
They have discovered a protein – called CIS – that acts as a brake to dampen natural killer cell activity. Blocking CIS increases anti-tumour activity and reduces melanoma growth in preclinical models.
Our researchers are now partnering with a drug company to develop inhibitors of CIS that may ultimately help patients fight cancer with their own immune system.
Immunotherapy for immune disorders
Immunotherapy can be used to dampen down harmful immune responses, for example in:
- coeliac disease, which is caused by an inappropriate immune reaction to the gluten protein found in wheat, rye and barley
- type 1 diabetes, which is caused by the immune system wrongly attacking healthy cells in the pancreas
Our researchers are performing a clinical trial pairing the diabetes immunotherapy with an immunosuppressive agent to test if the combination will slow the progression of type 1 diabetes.
Researchers:
Researchers have developed a way to potentially reduce the toxic side-effects of a type of immunotherapy, in findings that could overcome the pioneering treatment’s biggest limitation.
A Cure Brain Cancer Foundation fellowship will support Dr Ryan Cross to undertake research into new immunotherapy treatments for brain cancer in adults and children.
Our bodies are constantly fighting off the development of cells that lead to tumours. Researchers have now discovered a protein ‘brake’ within Natural Killer cells that controls their ability to destroy their target tumour cells.
Funding from Carrie Bickmore’s Beanies 4 Brain Cancer Foundation is helping to advance immunotherapy treatments
A novel approach to immunotherapy design could pave the way for new treatments for people with an aggressive form of brain cancer called glioblastoma.